Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono PharmacareNSE:MONOPHARMA 9 EV-to-FCF is 123.35 as of Jul. 25, 2026. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 405 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 92.35% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mono Pharmacare's Enterprise Value is ₹723 Mil.
Mono Pharmacare's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹6 Mil. Therefore, Mono Pharmacare's EV-to-FCF for today is 123.35.
The historical rank and industry rank for Mono Pharmacare's EV-to-FCF or its related term are showing as below:
NSE:MONOPHARMA'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.7 Med: -11.7 Max: 124.1
Current: 124.1
During the past 5 years, the highest EV-to-FCF of Mono Pharmacare was 124.10. The lowest was -22.70. And the median was -11.70.
NSE:MONOPHARMA's EV-to-FCF is ranked worse than 92.35% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 17.87
vs NSE:MONOPHARMA: 124.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mono Pharmacare's PE Ratio (TTM) for today is calculated as:
Mono Pharmacare's share price for today is ₹10.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mono Pharmacare EV-to-FCF Related Terms
Mono Pharmacare EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's EV-to-FCF falls into.
Mono Pharmacare's current Enterprise Value is ₹723 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a EV-to-FCF of 123.35 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mono Pharmacare and its competitors. According to the industry distribution chart, Mono Pharmacare ranks #374 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 92.3%.
Is Mono Pharmacare's EV-to-FCF too high?
Mono Pharmacare's current EV-to-FCF is 123.35. The Healthcare Providers & Services industry median EV-to-FCF is 17.87. Mono Pharmacare's value of 123.35 is 590.3% above this industry median. Based on the distribution chart, Mono Pharmacare ranks #374 out of 405 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #374 out of 405 companies for EV-to-FCF. This places Mono Pharmacare in the lower half of its industry. The industry median EV-to-FCF is 17.87. Mono Pharmacare's value of 123.35 is 590.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.87, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current EV-to-FCF of 123.35 is 590.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current EV-to-FCF is 123.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current EV-to-FCF of 123.35. The current EV-to-FCF is 123.35 and 590.3% above the Healthcare Providers & Services industry median of 17.87. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current EV-to-FCF is 123.35 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
